Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $15.57.
A number of research firms have recently issued reports on FULC. The Goldman Sachs Group upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $6.00 to $15.00 in a report on Monday, May 13th. Piper Sandler increased their target price on shares of Fulcrum Therapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Oppenheimer cut their price target on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, May 14th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, May 14th. Finally, Royal Bank of Canada initiated coverage on Fulcrum Therapeutics in a report on Wednesday, March 13th. They set an “outperform” rating and a $14.00 target price on the stock.
Get Our Latest Analysis on Fulcrum Therapeutics
Institutional Trading of Fulcrum Therapeutics
Fulcrum Therapeutics Trading Up 4.7 %
NASDAQ:FULC opened at $6.68 on Friday. The firm has a market cap of $415.19 million, a price-to-earnings ratio of -4.18 and a beta of 2.34. Fulcrum Therapeutics has a twelve month low of $3.03 and a twelve month high of $13.70. The company has a 50-day moving average of $7.50 and a 200-day moving average of $7.96.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative return on equity of 40.60% and a negative net margin of 3,470.05%. On average, research analysts forecast that Fulcrum Therapeutics will post -1.24 earnings per share for the current year.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
See Also
- Five stocks we like better than Fulcrum Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- McDonald’s Stock: Balancing Value and Innovation
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- MarketBeat Week in Review – 6/17 – 6/21
- Financial Services Stocks Investing
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.